Payment overview · 2025
General Payments
$616.89
21 reported records · 10 companies
Healthcare provider profile · identity verified
Timothy D Hooper
Allopathic & Osteopathic Physicians|Internal Medicine · SONORA, CA · NPI 1629097399
Verified facts
What the public records show
CMS Open Payments records show Timothy D Hooper received $616.89 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.04 | 34.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.51 | 24.4% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.02 | 9.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.52 | 9.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.22 | 4.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $24.95 | 4.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.07 | 3.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.50 | 3.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.84 | 2.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.22 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.89 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $212.04 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $195.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $195.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.51 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $30.22 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $30.22 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| REGRANEX Normalized: regranex |
Drug | Smith+Nephew, Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 518 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 117 |
| Gabapentin | Gabapentin | 432 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 56 |
| Losartan Potassium | Losartan Potassium | 257 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 243 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 55 |
| Tramadol Hcl | Tramadol Hcl | 215 | 36 |
| Alprazolam | Alprazolam | 197 | 26 |
| Lisinopril | Lisinopril | 189 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 53 |
| Buprenorphine Hcl | Buprenorphine Hcl | 181 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 43 |
| Pregabalin | Pregabalin | 176 | 28 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 174 | 24 |
| Metformin Hcl | Metformin Hcl | 174 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 36 |
| Eliquis | Apixaban | 165 | 26 |
| Baclofen | Baclofen | 159 | 36 |
| Furosemide | Furosemide | 158 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 32 |
| Trazodone Hcl | Trazodone Hcl | 127 | 25 |
| Benazepril Hcl | Benazepril Hcl | 126 | 35 |
| Carvedilol | Carvedilol | 117 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 22 |
| Montelukast Sodium | Montelukast Sodium | 110 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 29 |
| Lorazepam | Lorazepam | 107 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 27 |
| Omeprazole | Omeprazole | 102 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 21 |
| Potassium Chloride | Potassium Chloride | 90 | 32 |
| Rybelsus | Semaglutide | 90 | 17 |
| Famotidine | Famotidine | 88 | 26 |
| Mirtazapine | Mirtazapine | 83 | 18 |
| Celecoxib | Celecoxib | 82 | 19 |
| Ibuprofen | Ibuprofen | 79 | 18 |
| Methocarbamol | Methocarbamol | 79 | 15 |
| Allopurinol | Allopurinol | 78 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 78 | 21 |
| Glipizide | Glipizide | 76 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 24 |
| Finasteride | Finasteride | 73 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 12 |
| Xarelto | Rivaroxaban | 72 | 17 |
| Ondansetron Odt | Ondansetron | 70 | 18 |
| Azithromycin | Azithromycin | 69 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Meloxicam | Meloxicam | 69 | 18 |
| Buspirone Hcl | Buspirone Hcl | 67 | 16 |
| Simvastatin | Simvastatin | 66 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 24 |
| Buprenorphine | Buprenorphine | 59 | suppressed |
| Olanzapine | Olanzapine | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 13 |
| Testosterone | Testosterone | 57 | 14 |
| Estradiol | Estradiol | 56 | 17 |
| Acyclovir | Acyclovir | 55 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | suppressed |
| Atenolol | Atenolol | 53 | 16 |
| Potassium Citrate Er | Potassium Citrate | 53 | 21 |
| Levofloxacin | Levofloxacin | 52 | 33 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 49 | 11 |
| Sertraline Hcl | Sertraline Hcl | 49 | 14 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Fentanyl | Fentanyl | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 45 | 13 |
| Verapamil Hcl | Verapamil Hcl | 45 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 17 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | 12 |
| Prednisone | Prednisone | 39 | 17 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 20 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | suppressed |
| Promethegan | Promethazine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | 11 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Febuxostat | Febuxostat | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Butrans | Buprenorphine | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.89 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, COLLAGENASE SANTYL, FANAPT, FARXIGA, HETLIOZ, Kerendia, Korlym, LEQVIO, MOUNJARO, REGRANEX, SUBLOCADE, TRELEGY ELLIPTA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error